Kedrion Biopharma showcases a significant 10% growth for 2024 along with the launch of its new brand identity aimed at enhancing patient therapy access.

Kedrion Biopharma announces that COAGADEX® has received Orphan Drug Designation from the FDA for acquired Factor X deficiency, with clinical trials underway.

Kedrion Biopharma's new IVIG treatment, QIVIGY®, has received FDA approval to aid adults with Primary Humoral Immunodeficiency, marking a significant milestone for the company.

Kedrion Biopharma is leading the conversation on secondary immunodeficiencies at IPIC 2025, emphasizing patient care and innovative therapies.

Kedrion Biopharma participates in IPIC 2025 focusing on secondary immunodeficiencies. The event offers insights into cutting-edge therapeutic advancements.

CASTELVECCHIO PASCOLI (LUCCA) (ITALPRESS) – Kedrion Biopharma, azienda specializzata nel settore biofarmaceutico e dedita alla raccolta e frazionamento del plasma, ha presentato la sua nuova identità e i risultati finanziari per il 2024. L’annuncio della rinnovata Kedrion evidenzia l’impegno dell’azienda nello sviluppo di terapie per patologie gravi, debilitanti e per malattie rare e ultra-rare. Nel 2024 Kedrion ha registrato una crescita a doppia cifra, con un fatturato che ha raggiunto 1.578 milioni di euro, segnando un aumento del +10% rispetto all’anno precedente.

Kedrion Biopharma showcases its commitment to advancing patient care by participating in IPIC 2025, focusing on Secondary Immunodeficiencies in hematologic malignancies.

Kedrion has announced that the FDA granted Orphan Drug Designation for its investigational treatment addressing Congenital Aceruloplasminemia, a rare genetic condition.

YouTube video by Farmaceutica Younger

Kedrion Biopharma is actively promoting awareness of Plasminogen Deficiency through diverse virtual and in-person events aimed at educating the public about this rare genetic disorder.

Kedrion's innovative plasma-derived therapy has been given Orphan Drug Designation by the EMA, targeting a rare genetic condition known as Aceruloplasminemia.

Kedrion Biopharma Inc. has expanded the distribution network for Ryplazim, the sole FDA-approved treatment for patients with plasminogen deficiency type 1 (PLGD-1), ensuring better access for all.

Kedrion Biopharma highlights its commitment to patient care and innovation in the field of immunodeficiencies, participating in IPIC 2025 and hosting a symposium.

Kedrion's treatment for aceruloplasminemia has received Orphan Drug Designation from EMA, marking a significant advance for rare disease therapies.

Kedrion's innovative plasma-derived treatment for Congenital Aceruloplasminemia has received Orphan Drug Designation from EMA, highlighting a pivotal advancement for patients.